Northern Trust Corp decreased its position in shares of Nantkwest Inc (NASDAQ:NK) by 8.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 281,886 shares of the biotechnology company’s stock after selling 25,057 shares during the period. Northern Trust Corp owned approximately 0.36% of Nantkwest worth $862,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. Renaissance Technologies LLC increased its position in shares of Nantkwest by 72.2% in the second quarter. Renaissance Technologies LLC now owns 520,400 shares of the biotechnology company’s stock worth $1,592,000 after purchasing an additional 218,200 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Nantkwest by 144.2% in the second quarter. Dimensional Fund Advisors LP now owns 216,272 shares of the biotechnology company’s stock worth $662,000 after purchasing an additional 127,694 shares during the period. Millennium Management LLC increased its position in shares of Nantkwest by 402.4% in the first quarter. Millennium Management LLC now owns 156,744 shares of the biotechnology company’s stock worth $610,000 after purchasing an additional 125,544 shares during the period. Finally, Bank of New York Mellon Corp increased its position in shares of Nantkwest by 40.5% in the second quarter. Bank of New York Mellon Corp now owns 170,271 shares of the biotechnology company’s stock worth $521,000 after purchasing an additional 49,040 shares during the period. Hedge funds and other institutional investors own 13.55% of the company’s stock.

In other news, Director Steve Gorlin sold 115,930 shares of Nantkwest stock in a transaction dated Wednesday, November 14th. The stock was sold at an average price of $2.21, for a total transaction of $256,205.30. Following the sale, the director now directly owns 149,230 shares of the company’s stock, valued at $329,798.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 469,251 shares of company stock worth $919,880 over the last three months. Insiders own 72.30% of the company’s stock.

A number of brokerages recently commented on NK. Zacks Investment Research upgraded Nantkwest from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research report on Wednesday, October 10th. BidaskClub upgraded Nantkwest from a “sell” rating to a “hold” rating in a research report on Friday, September 28th. Citigroup cut Nantkwest from a “neutral” rating to a “sell” rating in a research report on Tuesday, October 16th. ValuEngine upgraded Nantkwest from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $3.50 target price on shares of Nantkwest in a research report on Thursday, November 15th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $3.58.

Nantkwest stock opened at $1.67 on Thursday. Nantkwest Inc has a 12-month low of $1.62 and a 12-month high of $5.47. The stock has a market capitalization of $132.31 million, a price-to-earnings ratio of -1.39 and a beta of 3.09. The company has a current ratio of 3.31, a quick ratio of 3.31 and a debt-to-equity ratio of 0.04.

COPYRIGHT VIOLATION NOTICE: “Northern Trust Corp Sells 25,057 Shares of Nantkwest Inc (NK)” was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/northern-trust-corp-sells-25057-shares-of-nantkwest-inc-nk/2665260.html.

Nantkwest Company Profile

NantKwest, Inc, a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.

Featured Article: What are Institutional Investors?

Institutional Ownership by Quarter for Nantkwest (NASDAQ:NK)

Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.